Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | IDO1 | P14902 | 1/20 | 0.31 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.30 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.30 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1151212 | 1.00 | KMT2A (0.40) | KMT2APOLBIDO1MTNR1AMTNR1B | |
| SCHEMBL24654022 | 0.85 | KMT2A (0.38) | KMT2APOLBZDHHC2HSD17B10 | |
| SCHEMBL13617146 | 0.85 | MAPT (0.40) | KMT2APOLBIDO1ZDHHC2 | |
| SCHEMBL13066415 | 0.81 | KMT2A (0.41) | KMT2APOLBIDO1MTNR1AMTNR1B | |
| SCHEMBL21597555 | 0.81 | KMT2A (0.41) | KMT2APOLBIDO1MTNR1AMTNR1B | |
| SCHEMBL21597554 | 0.81 | KMT2A (0.41) | KMT2APOLBIDO1MTNR1AMTNR1B | |
| SCHEMBL14996220 | 0.81 | ZDHHC2 (0.50) | ZDHHC2 | |
| SCHEMBL3421932 | 0.81 | ZDHHC2 (0.50) | ZDHHC2 | |
| SCHEMBL13593769 | 0.81 | KMT2A (0.39) | KMT2APOLBIDO1 | |
| SCHEMBL13630803 | 0.80 | ZDHHC2 (0.52) | ZDHHC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7884244-B2 | Therapeutic fluoroethylcyano guanidines | ALLERGAN, INC. (US) | 2011-02-08 | — | — | US | disclosed |
| US-7884244-B2 | Therapeutic fluoroethylcyano guanidines | ALLERGAN, INC. (US) | 2011-02-08 | — | — | US | disclosed |
| US-20080255230-A1 | THERAPEUTIC FLUOROETHYLCYANO GUANIDINES | ALLERGAN, INC. | 2008-10-16 | — | — | US | disclosed |
| US-20080255230-A1 | THERAPEUTIC FLUOROETHYLCYANO GUANIDINES | ALLERGAN, INC. | 2008-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255230-A1 | THERAPEUTIC FLUOROETHYLCYANO GUANIDINES | PDE3A, PDE2A, PDE3B | KMT2A 2005/4885POLB 2957/4885IDO1 2321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.